{
    "title": "4‑Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ‑Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain",
    "id": "jm9b01256",
    "journal": "Journal of Medicinal Chemistry",
    "reactions": [
        {
            "text": "Epoxide 7 was prepared using Corey–Chaykovsky reagent, followed by thermal ring opening with arylamines 8, leading to aminoalcohols 9 in good yields. Acylation with an adequate acyl halide, 10, and final intramolecular cyclization by treatment with potassium tert-butoxide at low temperatures rendered spirocyclic compounds 12.",
            "product": "9",
            "reactants": "7, 8",
            "reaction type": "thermal ring opening"
        },
        {
            "text": "Epoxide 7 was prepared using Corey–Chaykovsky reagent, followed by thermal ring opening with arylamines 8, leading to aminoalcohols 9 in good yields. Acylation with an adequate acyl halide, 10, and final intramolecular cyclization by treatment with potassium tert-butoxide at low temperatures rendered spirocyclic compounds 12.",
            "product": "12",
            "reactants": "10, potassium tert-butoxide",
            "temperature": "low",
            "reaction type": "Acylation, intramolecular cyclization"
        },
        {
            "text": "In the case of simple R3 groups, such as benzyl and phenethyl, the N-substituted piperidones (16) were commercially available and were used to prepare compounds 15 bearing the substituent R3 right from the start. This allowed diversification in substituents R1-R2 (Scheme 2) by building the spirobicyclic core following a similar strategy to that described in Scheme 1. The related spiro compound 20 was prepared from aminoalcohol 18-1 (where R1 is H and n is 1) upon treatment with carbonyldiimidazole (CDI).",
            "product": "20",
            "reactants": "CDI, carbonyldiimidazole, 18-1"
        },
        {
            "text": "In an analogous way to that described in Scheme 2, the pyrrolidinyl derivative 21 (Table 1) was prepared starting from N-benzylpyrrolidin-3-one with final exchange of R3 group to install the phenethyl chain present in compound 21 by conventional N-debenzylation followed by N-alkylation, as described in the Experimental Section5.",
            "product": "21",
            "reactants": "N-benzylpyrrolidin-3-one",
            "reaction type": "N-debenzylation, N-alkylation"
        },
        {
            "text": "Compounds bearing a spirocyclopropyl group in position 2 were synthesized (Scheme 4) using 4-methoxybenzyl (PMB) as N-protecting group. The key step was the acylation of aminoalcohol 30 with a conveniently functionalized acid chloride 31, followed by treatment with excess of potassium tert-butoxide, which provided two concomitant cyclizations to yield the spirocyclopropyl compound 33 in 48% yield (two steps). Boc deprotection and introduction of the phenethyl chain was performed as described in Scheme 1 to render 36. Finally, PMB group removal using cerium ammonium nitrate (CAN) and arylation under Ullmann or Buchwald–Hartwig coupling conditions provided compounds 15m and 15au.",
            "product": "33",
            "reactants": "30, 31, potassium tert-butoxide",
            "yield": "48%",
            "reaction type": "cyclizations, acylation"
        },
        {
            "text": "Compounds bearing a spirocyclopropyl group in position 2 were synthesized (Scheme 4) using 4-methoxybenzyl (PMB) as N-protecting group. The key step was the acylation of aminoalcohol 30 with a conveniently functionalized acid chloride 31, followed by treatment with excess of potassium tert-butoxide, which provided two concomitant cyclizations to yield the spirocyclopropyl compound 33 in 48% yield (two steps). Boc deprotection and introduction of the phenethyl chain was performed as described in Scheme 1 to render 36. Finally, PMB group removal using cerium ammonium nitrate (CAN) and arylation under Ullmann or Buchwald–Hartwig coupling conditions provided compounds 15m and 15au.",
            "product": "15m",
            "reaction type": "arylation",
            "catalyst": "cerium ammonium nitrate, CAN"
        },
        {
            "text": "Enantiopure compounds 15 were obtained by chiral preparative HPLC separation of the corresponding racemic mixtures, as indicated in the Supporting Informationes-2. The absolute configuration of the eutomers was assigned as (R) as established by chiral synthesis of compounds 15cR and 15asR. Starting from (S)-2-chloropropionyl chloride (10–1S, 95% ee) and following the procedure described in Scheme 2, with modified acylation conditions, the corresponding (S)-acyl derivative 19–1S was obtained. This was cyclized assuming inversion of configuration to give compound 15cR with 91% ee, as determined by chiral HPLC. In turn, compound 15asR was prepared from 10–1S using the procedure described in Scheme 3.",
            "product": "19–1S",
            "reactants": "95% ee, (S)-2-chloropropionyl chloride, (10–1S",
            "reaction type": "acylation"
        },
        {
            "text": "Enantiopure compounds 15 were obtained by chiral preparative HPLC separation of the corresponding racemic mixtures, as indicated in the Supporting Informationes-2. The absolute configuration of the eutomers was assigned as (R) as established by chiral synthesis of compounds 15cR and 15asR. Starting from (S)-2-chloropropionyl chloride (10–1S, 95% ee) and following the procedure described in Scheme 2, with modified acylation conditions, the corresponding (S)-acyl derivative 19–1S was obtained. This was cyclized assuming inversion of configuration to give compound 15cR with 91% ee, as determined by chiral HPLC. In turn, compound 15asR was prepared from 10–1S using the procedure described in Scheme 3.",
            "product": "15cR",
            "reactants": "95% ee), 19–1S, (S)-2-chloropropionyl chloride, (10–1S",
            "reaction type": "assuming inversion of configuration, cyclized"
        },
        {
            "text": "Enantiopure compounds 15 were obtained by chiral preparative HPLC separation of the corresponding racemic mixtures, as indicated in the Supporting Informationes-2. The absolute configuration of the eutomers was assigned as (R) as established by chiral synthesis of compounds 15cR and 15asR. Starting from (S)-2-chloropropionyl chloride (10–1S, 95% ee) and following the procedure described in Scheme 2, with modified acylation conditions, the corresponding (S)-acyl derivative 19–1S was obtained. This was cyclized assuming inversion of configuration to give compound 15cR with 91% ee, as determined by chiral HPLC. In turn, compound 15asR was prepared from 10–1S using the procedure described in Scheme 3.",
            "product": "15asR",
            "reactants": "10–1S",
            "reaction type": "chiral synthesis"
        },
        {
            "text": "Step 3: To a solution of 18-1 (578 mg, 1.86 mmol) in DCM (22 mL), TEA (0.62 mL, 4.47 mmol) was added and the mixture was cooled to 0 °C under a nitrogen atmosphere. Then a solution of 2-chloropropionyl chloride (10-1, 0.27 mL, 2.79 mmol) in DCM (22 mL) was added dropwise, and the reaction mixture was stirred at 0 °C for 2 h. Saturated aqueous NaHCO3 was then added, and it was extracted with DCM. The combined organic phases were washed with brine, dried over MgSO4, filtered, and concentrated to dryness to give 2-chloro-N-((4-hydroxy-1-phenethylpiperidin-4-yl)methyl)-N-phenylpropanamide (19-1) as an oil used in the next step without further purification (670 mg, 89%).",
            "product": "2-chloro-N-((4-hydroxy-1-phenethylpiperidin-4-yl)methyl)-N-phenylpropanamide",
            "reactants": "TEA, 18-1, 2-chloropropionyl chloride, NaHCO3, 10-1",
            "temperature": "0 °C",
            "time": "2 h",
            "solvent": "DCM"
        },
        {
            "text": "Step 3: To a solution of 18-1 (578 mg, 1.86 mmol) in DCM (22 mL), TEA (0.62 mL, 4.47 mmol) was added and the mixture was cooled to 0 °C under a nitrogen atmosphere. Then a solution of 2-chloropropionyl chloride (10-1, 0.27 mL, 2.79 mmol) in DCM (22 mL) was added dropwise, and the reaction mixture was stirred at 0 °C for 2 h. Saturated aqueous NaHCO3 was then added, and it was extracted with DCM. The combined organic phases were washed with brine, dried over MgSO4, filtered, and concentrated to dryness to give 2-chloro-N-((4-hydroxy-1-phenethylpiperidin-4-yl)methyl)-N-phenylpropanamide (19-1) as an oil used in the next step without further purification (670 mg, 89%).",
            "product": "(19-1)",
            "reactants": "TEA, NaHCO3, 2-chloropropionyl chloride (10-1, 18-1",
            "temperature": "0 °C",
            "time": "2 h",
            "solvent": "DCM"
        },
        {
            "text": "To a solution of 19-1 (670 mg, 1.67 mmol) in THF (28 mL), cooled to −78 °C using a dry ice/acetone bath, and potassium tert-butoxide solution (2.5 mL, 1 M in THF, 2.50 mmol) was added under a nitrogen atmosphere. The reaction mixture was then stirred at −30 °C for 3 h. Water was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO4, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO2, DCM/MeOH up to 10%) to give 2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (15c) as a cream solid (511 mg, 84%).",
            "product": "2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one",
            "reactants": "Water, 19-1, potassium tert-butoxide",
            "temperature": "78 °C, 30 °C",
            "time": "3 h",
            "solvent": "THF",
            "catalyst": "dry ice, acetone"
        },
        {
            "text": "To a solution of 19-1 (670 mg, 1.67 mmol) in THF (28 mL), cooled to −78 °C using a dry ice/acetone bath, and potassium tert-butoxide solution (2.5 mL, 1 M in THF, 2.50 mmol) was added under a nitrogen atmosphere. The reaction mixture was then stirred at −30 °C for 3 h. Water was added, and it was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO4, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO2, DCM/MeOH up to 10%) to give 2-methyl-9-phenethyl-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (15c) as a cream solid (511 mg, 84%).",
            "product": "15c",
            "reactants": "Water, 19-1, potassium tert-butoxide",
            "temperature": "78 °C, 30 °C",
            "time": "3 h",
            "solvent": "THF"
        },
        {
            "text": "Step 3: To a solution of compound 30 (9.94 g, 28.36 mmol) and TEA (9.5 mL, 68.16 mmol) in DCM (500 mL), a solution of 2-bromo-4-chlorobutanoyl chloride (31) (9.35 g, 42.53 mmol) in DCM (200 mL) was added dropwise at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 2 h. Saturated aqueous NaHCO3 was added, and it was extracted with DCM. The combined organic phases were dried over MgSO4, filtered, and concentrated to dryness to give crude tert-butyl 4-((2-bromo-4-chloro-N-(4-methoxybenzyl)butanamido)methyl)-4-hydroxypiperidine-1-carboxylate (32) as an orange oil (15.10 g, quantitative). To a solution of crude 32 (14.80 g, 27.72 mmol) in THF (185 mL), cooled to 0 °C under a nitrogen atmosphere, potassium tert-butoxide solution (111 mL, 1 M in THF, 111.00 mmol) was slowly added, and the reaction mixture was stirred at 0 °C for 2 h. Saturated aqueous NH4Cl was then added, and it was extracted with ethyl acetate. The organic phases were combined, dried over MgSO4, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO2, DCM/MeOH up to 10%) to give tert-butyl 12-(4-methoxybenzyl)-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane-8-carboxylate (33) as a yellow oil (5.51 g, 48%).",
            "product": "tert-butyl 4-((2-bromo-4-chloro-N-(4-methoxybenzyl)butanamido)methyl)-4-hydroxypiperidine-1-carboxylate",
            "reactants": "(31), 30, 2-bromo-4-chlorobutanoyl chloride",
            "temperature": "0 °C",
            "time": "2 h",
            "solvent": "DCM",
            "catalyst": "nitrogen"
        },
        {
            "text": "Step 3: To a solution of compound 30 (9.94 g, 28.36 mmol) and TEA (9.5 mL, 68.16 mmol) in DCM (500 mL), a solution of 2-bromo-4-chlorobutanoyl chloride (31) (9.35 g, 42.53 mmol) in DCM (200 mL) was added dropwise at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 2 h. Saturated aqueous NaHCO3 was added, and it was extracted with DCM. The combined organic phases were dried over MgSO4, filtered, and concentrated to dryness to give crude tert-butyl 4-((2-bromo-4-chloro-N-(4-methoxybenzyl)butanamido)methyl)-4-hydroxypiperidine-1-carboxylate (32) as an orange oil (15.10 g, quantitative). To a solution of crude 32 (14.80 g, 27.72 mmol) in THF (185 mL), cooled to 0 °C under a nitrogen atmosphere, potassium tert-butoxide solution (111 mL, 1 M in THF, 111.00 mmol) was slowly added, and the reaction mixture was stirred at 0 °C for 2 h. Saturated aqueous NH4Cl was then added, and it was extracted with ethyl acetate. The organic phases were combined, dried over MgSO4, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO2, DCM/MeOH up to 10%) to give tert-butyl 12-(4-methoxybenzyl)-13-oxo-4-oxa-8,12-diazadispiro[2.1.5.3]tridecane-8-carboxylate (33) as a yellow oil (5.51 g, 48%).",
            "product": "32",
            "reactants": "2-bromo-4-chlorobutanoyl chloride (31), TEA, 30, NaHCO3",
            "temperature": "0 °C",
            "time": "2 h",
            "solvent": "DCM",
            "catalyst": "nitrogen"
        },
        {
            "text": "To a solution of 4-(2-methoxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (15p, 116 mg, 0.29 mmol) in DCM (6 mL), cooled to −78 °C under a nitrogen atmosphere, boron tribromide solution (1.5 mL, 1 M in DCM, 1.50 mmol) was added dropwise. The reaction mixture was allowed to warm to −20 °C for 2 h. Then, 6 N NaOH aqueous solution was added until pH 9–10, and it was extracted with DCM. The combined organic phases were washed with brine, dried over MgSO4, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO2, DCM/MeOH up to 10%) to give 4-(2-hydroxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one (15q) as a white solid (42 mg, 35%).",
            "product": "4-(2-hydroxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9",
            "reactants": "(15p, 4-(2-methoxyphenyl)-2-methyl-9-phenethyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one, 116 mg, 0.29 mmol) boron tribro",
            "temperature": "78 °C",
            "time": "2 h",
            "solvent": "DCM",
            "catalyst": "nitrogen"
        },
        {
            "text": "Step 2: To a solution of 9-1 (4.90 g, 15.99 mmol)) in DCM (180 mL), TEA (5.3 mL, 38.03 mmol) was added and the mixture was cooled to 0 °C under a nitrogen atmosphere. Then 2-chloropropionyl chloride (10-1, 2.3 mL, 23.69 mmol) was added dropwise, and the reaction mixture was stirred at 0 °C for 2 h. Saturated aqueous NaHCO3 was added, the phases were separated, and the aqueous phase was extracted with DCM. The combined organic phases were dried over MgSO4, filtered, and concentrated to dryness to give tert-butyl 4-((2-chloro-N-phenylpropanamido)methyl)-4-hydroxypiperidine-1-carboxylate (11-1) as a cream solid used in the next step without purification (6.40 g, quantitative). 1H NMR (400 MHz, CDCl3) δ 7.50–7.37 (m, 3H), 7.35–7.23 (br s, 2H), 4.28 (q, J = 6.6 Hz, 1H), 3.81 (m, 4H), 3.15 (br s, 2H), 1.66–1.59 (m, 2H), 1.58 (d, J = 6.6 Hz, 3H), 1.42 (s, 9H), 1.41–1.35 (m, 2H).",
            "product": "tert-butyl 4-((2-chloro-N-phenylpropanamido)methyl)-4-hydroxypiperidine-1-carboxylate, 11-1)",
            "reactants": "TEA, 9-1, 2-chloropropionyl chloride, NaHCO3, 10-1",
            "temperature": "0 °C",
            "time": "2 h",
            "solvent": "DCM"
        },
        {
            "text": "Step 3: To a solution of 11-1 (6.40 g, 16.12 mmol) in THF (280 mL), cooled to −78 °C using a dry ice/acetone bath, potassium tert-butoxide solution (25 mL, 1 M in THF, 25.00 mmol) was added under a nitrogen atmosphere. The reaction mixture was stirred at −78 °C for 30 min and then at −30 °C for 4 h. Saturated aqueous NaHCO3 was added, and it was extracted with DCM. The combined organic phases were dried over MgSO4, filtered, and concentrated to dryness. The residue was purified by flash chromatography (SiO2, DCM/MeOH up to 10%) to give tert-butyl 2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5] undecane-9-carboxylate (12-1) as a white solid (4.56 g, 79%).",
            "product": "12-1), tert-butyl 2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5] undecane-9-carboxylate",
            "reactants": "NaHCO3, potassium tert-butoxide, 11-1",
            "temperature": "78 °C, 30 °C",
            "time": "4 h, 30 min",
            "solvent": "THF",
            "catalyst": "dry ice, acetone"
        },
        {
            "text": "Starting from racemic 15al, a chiral preparative HPLC separation (column, Chiralpak ASH; temperature, ambient; flow: 9 mL/min; eluent, n-heptane/EtOH 80/20 v/v) was carried out to give 2R-N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide (15alR) as a white solid (92 mg, recovery yield 41%) with ee 99% (chiral HPLC) and [α]D20 43 (c 0.07, CHCl3). HPLC-MS: purity 100%.",
            "product": "2R-N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide",
            "reactants": "15al",
            "yield": "41%), recovery yield",
            "temperature": "ambient",
            "solvent": "n-heptane EtOH"
        },
        {
            "text": "Starting from racemic 15al, a chiral preparative HPLC separation (column, Chiralpak ASH; temperature, ambient; flow: 9 mL/min; eluent, n-heptane/EtOH 80/20 v/v) was carried out to give 2R-N-(3-(2-(2-methyl-3-oxo-4-phenyl-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenyl)acetamide (15alR) as a white solid (92 mg, recovery yield 41%) with ee 99% (chiral HPLC) and [α]D20 43 (c 0.07, CHCl3). HPLC-MS: purity 100%.",
            "product": "15alR",
            "reactants": "15al",
            "yield": "41%)",
            "temperature": "ambient",
            "solvent": "n-heptane EtOH"
        },
        {
            "text": "Step 1: A mixture of 2-benzyl-9-phenyl-6-oxa-2,9-diazaspiro[4.5]decan-8-one (42, prepared following the procedure described for compound 15c, but starting from N-benzyl-pyrrolidin-3-one and 2-chloroacetyl chloride; 124 mg, 0.38 mmol) and palladium (12 mg, 10 wt % on charcoal) in MeOH (10 mL) was stirred at rt under 3 bar of hydrogen for 3 days.",
            "product": "42",
            "reactants": "15c, 2-chloroacetyl chloride, N-benzyl-pyrrolidin-3-one",
            "time": "3 days",
            "solvent": "MeOH",
            "catalyst": "palladium"
        }
    ]
}